https://www.selleckchem.com/products/cx-5461.html
This study aimed to compare the efficacy, safety and metabolic effects of once-weekly pegylated human growth hormone (PEG-rhGH) with daily rhGH in patients with growth hormone deficiency (GHD). 48 patients enrolled in this 12-month single-center, open-label, prospective, randomized controlled trial is allocated to PEG-rhGH 0.12mg/kg/w and 0.20mg/kg/w treatment. Besides, the control group allocated 23 patients treated with daily rhGH 0.28mg/kg/w matched with sex, age, and baseline IGF-1 levels. The primary endpoint included height veloci
Aimer
Commentaire
Partagez
